OKYO Pharma LTD

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

• OKYO demonstrates continued commitment to optometry and ophthalmology
  

LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026
New Orleans, Louisiana

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Presentation Date/Time: Thursday, October 8, 2026, 1:29 PM CT
Breakout: Anterior Segment, Room 243-245
Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma
Moderators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD

American Academy of Optometry takes place September 30 - October 1 in Anaheim where the leadership team will engage leading optometric experts.

American Academy of Ophthalmology takes place October 9-12 in New Orleans where the leadership team will engage with leading ophthalmology experts.

The Company's continued presence at leading ophthalmic meetings supports its commitment to engaging both optometrists and ophthalmologists, who both play a role in the diagnosis and care of patients with neuropathic corneal pain (NCP).

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com